Beta-lactam Pharmacokinetics in Secondary Care

Launched by IMPERIAL COLLEGE LONDON · Jan 24, 2017

Keywords

ClinConnect Summary

STUDY PARTICIPANTS

* Participants receiving oral or intravenous therapy will be included in this study.
* Drug level sampling will be undertaken once the participant is at steady state (after at least 5 doses have been administered to those on treatment).
* All patients will be consented using the participation information leaflet and consent form provided in appendix 1.

DRUG LEVEL SAMPLING

* Patients will be identified for inclusion, and researchers will discuss inclusion in the study with the patient and provide clinical information for them to consider. Individuals will be recruited f...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult subjects over 18 years old
• • Capacity to consent to participation
• • Receiving target antimicrobial (amoxicillin, amoxcillin-clavulanate, cefuroxime, ceftriaxone, flucloxacillin, meropenem, piperacillin-tazobactam) for at least 5 doses prior to sampling
• • Appropriate venous access (or for venous access to be gained)
• Exclusion Criteria:
• • Children under 18 years old
• • Lacking capacity or prisoner
• • Anaemia or bleeding disorder, deemed significant by the patients physician
• • Patient's physician deems that they are not suitable for inclusion in the study
• • Patients unlikely to be receiving agent for study period